81 related articles for article (PubMed ID: 21112630)
41. Effect of Wnt inhibitors in pancreatic cancer.
Wall I; Schmidt-Wolf IG
Anticancer Res; 2014 Oct; 34(10):5375-80. PubMed ID: 25275031
[TBL] [Abstract][Full Text] [Related]
42. Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma.
Schmeel LC; Schmeel FC; Schmidt-Wolf IG
Anticancer Res; 2016 Jul; 36(7):3395-400. PubMed ID: 27354598
[TBL] [Abstract][Full Text] [Related]
43. The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of haematologic malignancy.
Weir SJ; Patton L; Castle K; Rajewski L; Kasper J; Schimmer AD
J Clin Pharm Ther; 2011 Apr; 36(2):128-34. PubMed ID: 21366640
[TBL] [Abstract][Full Text] [Related]
44. Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells.
Eberhard Y; McDermott SP; Wang X; Gronda M; Venugopal A; Wood TE; Hurren R; Datti A; Batey RA; Wrana J; Antholine WE; Dick JE; Schimmer AD
Blood; 2009 Oct; 114(14):3064-73. PubMed ID: 19589922
[TBL] [Abstract][Full Text] [Related]
45. GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.
Raab MS; Breitkreutz I; Anderhub S; Rønnest MH; Leber B; Larsen TO; Weiz L; Konotop G; Hayden PJ; Podar K; Fruehauf J; Nissen F; Mier W; Haberkorn U; Ho AD; Goldschmidt H; Anderson KC; Clausen MH; Krämer A
Cancer Res; 2012 Oct; 72(20):5374-85. PubMed ID: 22942257
[TBL] [Abstract][Full Text] [Related]
46. Griseofulvin: a novel addition to anti-multiple sclerosis ammunition?
Namazi MR
Mult Scler; 2005 Feb; 11(1):92. PubMed ID: 15732274
[No Abstract] [Full Text] [Related]
47. [Trends in development of novel therapeutic agents for multiple myeloma].
Kuroda J
Rinsho Ketsueki; 2012 Oct; 53(10):1699-708. PubMed ID: 23037742
[No Abstract] [Full Text] [Related]
48. Griseofulvin induces mitotic delay and aneuploidy in bone marrow cells of orally treated mice.
Pacchierotti F; Bassani B; Marchetti F; Tiveron C
Mutagenesis; 2002 May; 17(3):219-22. PubMed ID: 11971993
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxicity, Dermal Toxicity, and In Vivo Antifungal Effect of Griseofulvin-Loaded Vaterite Carriers Administered via Sonophoresis.
Verkhovskii RA; Kozlova AA; Lengert EV; Saveleva MS; Makarkin MA; Mylnikov AM; Navolokin NA; Bucharskaya AB; Terentyuk GS; Bosak IA; Vasilyeva NV; Svenskaya YI
ACS Infect Dis; 2023 May; 9(5):1137-1149. PubMed ID: 37104539
[TBL] [Abstract][Full Text] [Related]
50. Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.
Wang X; Raman N; Lemtiri-Chlieh G; Chang J; Jagtap S; Chowdhury DD; Ballew M; Carrieri FA; Nguyen T; Nugent K; Peck T; Levine MS; Chan A; Lam C; Malek R; Hoang T; Phillips R; Cheng Z; Taparra K; Connis N; Hann CL; Holland A; Tran PT; Lafargue A; Wang H
Mol Cancer Ther; 2023 Apr; 22(4):519-528. PubMed ID: 36752776
[TBL] [Abstract][Full Text] [Related]
51. Drug Targeting of Genomic Instability in Multiple Myeloma.
Beksac M; Balli S; Akcora Yildiz D
Front Genet; 2020; 11():228. PubMed ID: 32373151
[TBL] [Abstract][Full Text] [Related]
52. Utilizing ethacrynic acid and ciclopirox olamine in liver cancer.
Al-Dali AM; Weiher H; Schmidt-Wolf IGH
Oncol Lett; 2018 Nov; 16(5):6854-6860. PubMed ID: 30405829
[TBL] [Abstract][Full Text] [Related]
53. Clinically Applicable Inhibitors Impacting Genome Stability.
Prakash A; Garcia-Moreno JF; Brown JAL; Bourke E
Molecules; 2018 May; 23(5):. PubMed ID: 29757235
[TBL] [Abstract][Full Text] [Related]
54. Design, Synthesis, and Cytotoxicity Evaluation of Novel Griseofulvin Analogues with Improved Water Solubility.
Hamdy AK; Sheha MM; Abdel-Hafez AA; Shouman SA
Int J Med Chem; 2017; 2017():7386125. PubMed ID: 29362676
[TBL] [Abstract][Full Text] [Related]
55. Spatial and Temporal Profiling of Griseofulvin Production in Xylaria cubensis Using Mass Spectrometry Mapping.
Sica VP; Rees ER; Tchegnon E; Bardsley RH; Raja HA; Oberlies NH
Front Microbiol; 2016; 7():544. PubMed ID: 27199902
[TBL] [Abstract][Full Text] [Related]
56. Wnt/ß-catenin: a new therapeutic approach to acute myeloid leukemia.
Kim Y; Thanendrarajan S; Schmidt-Wolf IG
Leuk Res Treatment; 2011; 2011():428960. PubMed ID: 23213543
[TBL] [Abstract][Full Text] [Related]
57. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
58. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
59. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
60. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
